Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE

CENTERSTONE is the first global Phase III study to show a transmission reduction benefit with an antiviral used in the treatment of a respiratory viral illness. This new data may add to the benefits of Xofluza which is currently approved for treating symptoms and preventing infection following virus exposure.

Baloxavir marboxil significantly reduced the likelihood of influenza transmission from the infected patient to the household contacts. Treatment with baloxavir marboxil significantly reduced the risk of onward transmission of influenza within households, according to results from a phase 3 trial.

Roche RHHBY announced positive top-line results from a late-study on influenza drug, Xofluza. The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, taken within 48 hours of the symptoms’ onset,